Edition:
United States

Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

1.12AUD
30 Sep 2016
Change (% chg)

$0.01 (+0.90%)
Prev Close
$1.11
Open
$1.11
Day's High
$1.14
Day's Low
$1.11
Volume
302,173
Avg. Vol
1,194,864
52-wk High
$3.55
52-wk Low
$1.01

Latest Key Developments (Source: Significant Developments)

Mesoblast Ltd reports positive 24 month results in phase 2 trial for Chronic low back pain and initiation of phase 3 program
Wednesday, 14 Jan 2015 06:13pm EST 

Mesoblast Ltd:Says that it has presented positive 24-month results from its Phase 2 program for chronic low back pain.Additionally, announced that its Phase 3 program for this indication has been initiated.Mesoblast presented anticipated timelines for this Phase 3 program and noted that enrollment completion is expected in mid-2016, an interim analysis is expected in mid-2016 and top-line data are expected in mid-2017.The objective of the Phase 3 clinical program will be to confirm the positive outcomes from the Company's Phase 2 clinical trial.The primary endpoint will seek to confirm the treatment success seen in Phase 2 for MPC-06-ID against a control injection of saline.  Full Article

BRIEF-Mesoblast names Bill Burns as vice chairman

* Mesoblast appoints Bill Burns, former chief executive of Roche Pharmaceuticals, as vice chairman Source text for Eikon: Further company coverage: